Business
Notice of interim results
EKF Diagnostics Holdings PLC will release its interim results for the six months ending June 30, 2025, on Tuesday, September 16. The company will host a live online investor presentation on the same day at 10:30 am (BST) via the Investor Meet Company platform. A recording of the presentation, along with the slides and Q&A responses, will be available on the Investor Meet Company platform afterward. Disclaimer*
About this update from Ekf Diagnostics Holdings Plc
EKF Diagnostics Holdings plc ("EKF" or the "Company", or the "Group") Notice of interim results Investor presentation EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, confirms it will announce its interim results for the six months ended 30 June 2025 on Tuesday 16 September. Investor Presentation EKF Diagnostics will be hosting a live online presentation open to all existing and potential investors on Tuesday 16 September 2025 at 10.30am (BST), via the Investor Meet Company platform. Investors can sign up to Investor Meet Company for free and add to meet EKF Diagnostics via: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor Investors who already follow EKF on the Investor Meet Company platform will automatically be invited. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. EKF Diagnostics Holdings plc www.ekfdiagnostics.com Julian Baines, Executive Chair via Walbrook PR Gavin Jones, Chief Executive Officer Stephen Young, Chief Financial Officer Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000 Phil Davies / Oliver Platts Walbrook PR Limited Tel: +44 (0)20 7933 8780 or [email protected] Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com ) EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences offers contract fermentation services for clinically important enzymes and proteins, and the manufacture of Beta-Hydroxybutyrate (β-HB), used as a quantitative ketone test to identify patients suffering from diabetic ketoacidosis, as well as in many other clinical applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
View stock analysis, news, and events for Ekf Diagnostics Holdings Plc